The 5-year risk for recurrence was nearly 30% in men with unprovoked venous thromboembolism, despite negative D-dimer testing.
Progression-free survival and safety were better with this combination therapy than with standard sunitinib treatment.
Use of 5α-reductase inhibitors was associated with delayed diagnosis and worse mortality.
Specificity was high, but sensitivity was low; thus, autoantibody testing may rule in but not rule out ITP.
Relapsed or refractory patients had high response rates with anticipated, manageable toxicities.
An update to 2010 guidelines
Patients with untreated or relapsed blastic plasmacytoid dendritic-cell neoplasm achieved high response rates with tagraxofusp, a novel targeted cytotoxin.
Vitamin D3 supplementation, compared with placebo, did not result in significant improvement in relapse-free or progression-free survival in two new trials.
The FLOT regimen is a new standard of care for patients who can tolerate triplet chemotherapy.
Disease-free survival was longer with maintenance azacitidine than with observation in older patients who responded to induction chemotherapy.
Prof. Dr. med. Christoph Rochlitz
E-Mail: E-Mail anzeigen
In der vorliegenden Ausgabe von NEJM Journal Watch möchte ich Ihnen gerne wieder einige rezent publizierte Studien aus dem Bereich Onkologie/Hämatologie näherbringen.
Overall survival trended longer with the addition of palbociclib to endocrine therapy in patients with ER-positive/HER2-negative metastatic disease.
Adding atezolizumab to nab-paclitaxel prolonged progression-free survival in patients with metastatic triple-negative breast cancer.
Progression-free survival was prolonged with front-line brigatinib versus crizotinib.
Adding atezolizumab to chemotherapy significantly improved overall and progression-free survival.
Adding the PD-1 inhibitor pembrolizumab to carboplatin-taxane chemotherapy significantly improved response and survival.
Two-year overall survival was significantly improved with durvalumab versus placebo.
Long-term follow-up data confirm that axillary dissection is unnecessary in patients with minimal tumor burden in the sentinel nodes.
Progression-free survival was significantly longer with olaparib than with placebo.
Ipilimumab plus nivolumab proved safe and efficacious in a phase II trial.
Overall survival was noninferior and progression-free survival and response were superior with lenvatinib.